Mologen AG

ots Ad hoc-Service: Mologen Holding AG Mologen files patent application for gene-modified cell vaccine

Ad hoc-announcement edited and sent by DGAP. The sender is solely responsible for the contents of this announcement. ----------------------------------------------------- Berlin (ots Ad hoc-Service) - Mologen Holding AG, Berlin, Germany has developed a gene-modified cell vaccine for the treatment of kidney cancer. The company has filed a patent application for the vaccine which consists of several-fold gene-modified tumor cells. The vaccine has been tested in a clinical phase I/II trial and the results have been reported in the February issue of the journal Human Gene Therapy. The vaccine had no adverse effects, and manufacture and application of the vaccine were safe and reproducible. Following treatment, relevant clinical parameters improved in five out of the ten patients. One patient had a complete remission. No certain conclusions on efficacy can be drawn at this time, but the results suggest that the gene-modified cell vaccine can benefit advanced tumor patients with a large metastatic tumor burden. Mologen considers these findings as a confirmation of safety and efficacy of its MIDGE vector technology, which was developed and patented by Mologen for the use of genetic information in the treatment and prevention of diseases. Mologen is currently preparing for efficacy testing of the gene-modified cell vaccine in a clinical trial of phase III. Contact: Tel.: 841 788-13, Fax -50 End of message ----------------------------------------------------- Internet: Original-Content von: Mologen AG, übermittelt durch news aktuell

Themen in dieser Meldung

Das könnte Sie auch interessieren: